Login to Your Account



Bulls Proved Right: Hyperion's Ravicti Wins Approval in UCD

By Jennifer Boggs
Managing Editor

Friday, February 1, 2013
us_resized.jpg

The recent spike in Hyperion Therapeutics Inc.'s stock proved to be warranted Friday, when the FDA issued an approval for Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients, ages 2 and older.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription